221 articles in this topic
FDA approval of the first T1D delay drug nearly doubled islet autoantibody testing, but critical gaps remain in screening healthy children.
A new review links feline age-related obesity to SASP-driven chronic inflammation, offering translational insights for human metabolic disease.
The triple agonist retatrutide drives deep metabolic shifts beyond weight loss, improving key biomarkers of cardiovascular and insulin health.
Scientists identify IL-11 as a molecular brake on beige fat thermogenesis, and show blocking it improves metabolism in obese mice.
Diabetes drugs like empagliflozin show surprising anti-aging effects — mimicking caloric restriction and reducing senescent cell burden.
A rigorous MRI-based study finds that repeated hypoglycemia episodes leave brain glucose transport kinetics unchanged, challenging a leading hypothesis.
A novel endoluminal device implanted in the gut improved insulin sensitivity and weight control beyond what semaglutide achieved in a pig model.
A major Cochrane network meta-analysis protocol will rank all insulin regimens by efficacy and safety for adults with type 1 diabetes.
Landmark CKD trials enrolled mostly overweight patients — new evidence questions whether SGLT2 inhibitors work for lean, non-diabetic individuals.
A comprehensive review finds SGLT2 inhibitors reduce AKI risk in humans via hemodynamic, metabolic, and cellular protective pathways.
Wearable microneedle patches tap interstitial fluid to monitor glucose, lactate, and electrolytes in real time — no needles, no lab.
A novel conjugate merges GLP-1/GIP incretin signaling with pan-PPAR activation in one molecule, potentially revolutionizing metabolic therapy.
